Commitments and Contingencies	6 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of June 30, 2025, the Company had non-cancellable purchase commitments amounting to $130,087, of which $32,591 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $97,496 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen. Capital Commitments The Company had capital commitments amounting to $62,029 for the acquisition of property, plant and equipment as of June 30, 2025, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey. Co-Development Funding Commitment Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of June 30, 2025, the Company’s remaining co-development funding commitment was $242,916. Funding Commitment The Company had committed capital related to equity investments in the amount of $15,890. As of June 30, 2025, the remaining capital commitment was $6,740 and is expected to be paid from time to time over the investment period.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

Purchase Commitments

As of June 30, 2025, the Company had non-cancellable purchase commitments amounting to $130,087, of which $32,591 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $97,496 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.

Capital Commitments

The Company had capital commitments amounting to $62,029 for the acquisition of property, plant and equipment as of June 30, 2025, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey.

Co-Development Funding Commitment

Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of June 30, 2025, the Company’s remaining co-development funding commitment was $242,916.

Funding Commitment

The Company had committed capital related to equity investments in the amount of $15,890. As of June 30, 2025, the remaining capital commitment was $6,740 and is expected to be paid from time to time over the investment period.